| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,260,000 |
| Market
Cap: |
11.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5036 - $0.5036 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile PDS Biotechnology is a clinical-stage immunotherapy company developing a pipeline of molecularly targeted immunotherapies designed to overcome the limitations of existing immunotherapy and vaccine technologies. Co. owns the proprietary T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune®, for treatments in oncology and Infectimune™, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Co. is developing targeted product candidates to treat cancers including Human Papillomavirus associated cancers, melanoma, colorectal, lung, breast and prostate cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Leuthner Brian A |
President and CEO |
• • – |
2017-02-06 |
4 |
AS |
$9.52 |
$14,280 |
D/D |
(1,500) |
246,979 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2017-02-03 |
4 |
AS |
$9.69 |
$14,535 |
D/D |
(1,500) |
248,479 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2017-02-02 |
4 |
AS |
$9.61 |
$14,415 |
D/D |
(1,500) |
249,979 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2017-02-01 |
4 |
AS |
$9.38 |
$14,070 |
D/D |
(1,500) |
251,479 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2017-01-23 |
4 |
OE |
$2.04 |
$51,000 |
D/D |
25,000 |
595,602 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2016-12-01 |
4 |
AS |
$11.60 |
$87,000 |
D/D |
(7,500) |
252,979 |
|
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2016-10-03 |
4 |
AS |
$10.25 |
$76,844 |
D/D |
(7,500) |
260,479 |
|
- |
|
| Middlekauff W Bradford |
Senior VP, GC and Secretary |
• • – |
2016-08-08 |
4 |
B |
$9.43 |
$1,348 |
D/D |
143 |
10,000 |
2.66 |
- |
|
| Middlekauff W Bradford |
Senior VP, GC and Secretary |
• • – |
2016-08-05 |
4 |
B |
$9.48 |
$93,444 |
D/D |
9,857 |
9,857 |
2.74 |
- |
|
| Leuthner Brian A |
President and CEO |
• • – |
2016-08-01 |
4 |
AS |
$9.54 |
$71,582 |
D/D |
(7,500) |
267,979 |
|
- |
|
| New Leaf Venture Partners, L.l.c. |
Director |
– • – |
2016-06-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,344,868 |
|
- |
|
| Vaish Renu |
V.P., Global Reg. Affairs |
• • – |
2016-06-16 |
4 |
OE |
$5.13 |
$25,650 |
D/D |
5,000 |
5,350 |
|
- |
|
| Loughlin James J |
Director |
• • – |
2016-03-11 |
4 |
B |
$7.58 |
$22,901 |
I/I |
3,000 |
3,000 |
2.58 |
- |
|
| Healy James |
Director |
– • – |
2016-03-11 |
4 |
B |
$7.30 |
$3,951,641 |
I/I |
541,343 |
2,852,711 |
2.1 |
- |
|
| Spiegel Robert J. |
Director |
– • – |
2015-10-06 |
4 |
A |
$7.91 |
$12,253 |
D/D |
1,549 |
38,661 |
|
- |
|
| Spiegel Robert J. |
Director |
– • – |
2015-10-06 |
4 |
B |
$11.00 |
$33,000 |
D/D |
3,000 |
37,112 |
2.39 |
- |
|
| Spiegel Robert J. |
Director |
– • – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
34,112 |
34,112 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2015-10-06 |
4 |
A |
$7.90 |
$1,533 |
D/D |
194 |
570,602 |
|
- |
|
| Macdonald R. Loch |
Chief Scientific Officer |
• • – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
22,202 |
570,408 |
|
- |
|
| Healy James |
Director |
– • – |
2015-10-06 |
4 |
A |
$8.60 |
$461,519 |
I/I |
53,665 |
2,311,368 |
|
- |
|
| Healy James |
Director |
– • – |
2015-10-06 |
4 |
B |
$11.00 |
$4,950,000 |
I/I |
450,000 |
2,257,703 |
2.1 |
- |
|
| Healy James |
Director |
– • – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,807,703 |
1,807,703 |
|
- |
|
| Conti Kurt G |
Director |
– • – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
I/I |
847,896 |
789,420 |
|
- |
|
| Conti Kurt G |
Director |
– • – |
2015-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
324,541 |
324,541 |
|
- |
|
| Barer Sol J |
Director |
– • – |
2015-10-06 |
4 |
A |
$6.17 |
$78,575 |
I/I |
12,735 |
645,545 |
|
- |
|
122 Records found
|
|
Page 4 of 5 |
|
|
